Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has
been a model for cancer therapy development. Though most patients with CML have a …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer
research and therapy. These range from the identification of the first specific chromosomal …

Mutations in the kinase domain (KD) of BCR-ABL are the most prevalent mechanism of
acquired imatinib resistance in patients with chronic myeloid leukemia (CML). Here we …

Imatinib, a small-molecule ABL kinase inhibitor, is a highly effective therapy for early-phase
chronic myeloid leukaemia (CML), which has constitutively active ABL kinase activity owing …

Early T-cell precursor (ETP) acute lymphoblastic leukemia (ALL) is a recently described
subtype of T-ALL characterized by a unique immunophenotype and genomic profile, as well …

Background The FDA-approved small-molecule drug dasatinib is currently used as a
treatment for chronic myeloid leukemia (CML). However, the effects of dasatinib on …

Chronic Myeloid Leukemia (CML) is a clonal disease characterized by the presence of the
Philadelphia (Ph+) chromosome and its oncogenic product, BCR-ABL, a constitutively active …

Although imatinib, a BCR-ABL tyrosine kinase inhibitor, is used to treat acute Philadelphia
chromosome–positive (Ph+) leukemia, it does not prevent central nervous system (CNS) …